BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 20500495)

  • 1. Successful treatment of canine necrolytic migratory erythema (superficial necrolytic dermatitis) due to metastatic glucagonoma with octreotide.
    Oberkirchner U; Linder KE; Zadrozny L; Olivry T
    Vet Dermatol; 2010 Oct; 21(5):510-6. PubMed ID: 20500495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide.
    Kimbara S; Fujiwara Y; Toyoda M; Chayahara N; Imamura Y; Kiyota N; Mukohara T; Fukunaga A; Oka M; Nishigori C; Minami H
    Clin J Gastroenterol; 2014 Jun; 7(3):255-9. PubMed ID: 26183746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagonoma with necrolytic migratory erythema exhibiting responsiveness to subcutaneous octreotide injections.
    Lo CH; Ho CL; Shih YL
    QJM; 2014 Feb; 107(2):157-8. PubMed ID: 23389434
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful treatment of a patient with octreotide-resistant necrolytic migratory erythema.
    Bewley AP; Ross JS; Bunker CB; Staughton RC
    Br J Dermatol; 1996 Jun; 134(6):1101-4. PubMed ID: 8763433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-producing pancreatic endocrine tumors in two dogs with superficial necrolytic dermatitis.
    Gross TL; O'Brien TD; Davies AP; Long RE
    J Am Vet Med Assoc; 1990 Dec; 197(12):1619-22. PubMed ID: 2276959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Necrolytic migratory erythema without glucagonoma versus canine superficial necrolytic dermatitis: is hepatic impairment a clue to pathogenesis?
    Kasper CS; McMurry K
    J Am Acad Dermatol; 1991 Sep; 25(3):534-41. PubMed ID: 1655838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Necrolytic migratory erythema with myelodysplastic syndrome without glucagonoma.
    Technau K; Renkl A; Norgauer J; Ziemer M
    Eur J Dermatol; 2005; 15(2):110-2. PubMed ID: 15757825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of cutaneous manifestations within glucagonoma syndrome: necrolytic migratory erythema.
    Tolliver S; Graham J; Kaffenberger BH
    Int J Dermatol; 2018 Jun; 57(6):642-645. PubMed ID: 29450880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Necrolytic migratory erythema.
    Kovács RK; Korom I; Dobozy A; Farkas G; Ormos J; Kemény L
    J Cutan Pathol; 2006 Mar; 33(3):242-5. PubMed ID: 16466513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Octreotide-responsive necrolytic migratory erythema in a patient with pseudoglucagonoma syndrome.
    Virani S; Prajapati V; Devani A; Mahmood MN; Elliott JF
    J Am Acad Dermatol; 2013 Feb; 68(2):e44-6. PubMed ID: 23317985
    [No Abstract]   [Full Text] [Related]  

  • 11. Necrolytic migratory erythema associated with a glucagon-producing primary hepatic neuroendocrine carcinoma in a cat.
    Asakawa MG; Cullen JM; Linder KE
    Vet Dermatol; 2013 Aug; 24(4):466-9, e109-10. PubMed ID: 23738981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superficial necrolytic dermatitis associated with extrapancreatic glucagonoma in a dog.
    Mizuno T; Hiraoka H; Yoshioka C; Takeda Y; Matsukane Y; Shimoyama N; Morimoto M; Hayashi T; Okuda M
    Vet Dermatol; 2009 Feb; 20(1):72-9. PubMed ID: 19152590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical response of an atypical glucagonoma treated with a long-acting somatostatin analog].
    Bouin M; Aoust LD
    Gastroenterol Clin Biol; 2002 Oct; 26(10):926-9. PubMed ID: 12434103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Necrolytic migratory erythema and glucagonoma rising from pancreatic head.
    Tseng HC; Liu CT; Ho JC; Lin SH
    Pancreatology; 2013; 13(4):455-7. PubMed ID: 23890147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Necrolytic migratory erythema: case report and clinical review.
    Adam DN; Cohen PD; Ghazarian D
    J Cutan Med Surg; 2003; 7(4):333-8. PubMed ID: 14738101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Necrolytic Migratory Erythema: A Forgotten Paraneoplastic Condition.
    Tremblay C; Marcil I
    J Cutan Med Surg; 2017; 21(6):559-561. PubMed ID: 28662584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Necrolytic migratory erythema associated with hyperglucagonemia and neuroendocrine hepatic tumors.
    Marko PB; Miljković J; Zemljic TG
    Acta Dermatovenerol Alp Pannonica Adriat; 2005 Dec; 14(4):161-4, 166. PubMed ID: 16435046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid resolution of necrolytic migratory erythema after glucagonoma resection.
    Smith AP; Doolas A; Staren ED
    J Surg Oncol; 1996 Apr; 61(4):306-9. PubMed ID: 8628004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Malignant glucagonoma: an uncommon cause of new onset diabetes].
    Guerrero Vázquez R; Oliva Rodríguez R; Cuenca Cuenca JI; Sánchez Alberdi F; Navarro González E
    Endocrinol Nutr; 2011 Apr; 58(4):199-201. PubMed ID: 21334267
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical experience in diagnosis and treatment of glucagonoma syndrome.
    Zhang M; Xu X; Shen Y; Hu ZH; Wu LM; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):473-5. PubMed ID: 15313692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.